TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE)

• Main Authors: S. V. Vasilkov, A. P. Isaev, I. S. Pimenova, A. A. Ilyin, F. E. Sevryukov
• Format: Article
• Language: Russian
• Published: ABV-press 2017-11-01
• Series: Opuholi Golovy i Šei
• Subjects: highly differentiated thyroid cancer; radioiodresistance; targeted therapy
• Online Access: https://ogsh.abvpress.ru/jour/article/view/294

Highly differentiated thyroid cancer refers to the non-aggressive tumors due to the fact, that it can grow slowly and does not metastasize into surrounding tissues and organs. Modern medicine has the ability to cope with this disease, identify it in the early stages and begin timely treatment, which includes surgery and subsequent radioiodine therapy according to the indications. At the same time, the resistance of distant metastases to radioiodine therapy in patients with highly differentiated thyroid cancer significantly worsens the survival prognosis. Results of the use of chemotherapy do not allow recommend it as a therapy of choice. Today the achievements of antitumoral drug treatment are mainly related to the development of targeted therapy, namely, using individual tyrosine kinase inhibitors, in particular Sorafenib, which became the first registered in Russia drug, proved its therapeutic effectiveness in patients with this pathology, whose treatment options are currently extremely limited or absent.